Insulet (PODD) Stock
Tubeless insulin pump maker with recurring consumables revenue. Here's the price, business snapshot, and what's worth knowing about Insulet in August 2026.
Insulet Corporation (PODD) is a medical‑device company best known for its Omnipod tubeless insulin pump system, aimed at people with type 1 and insulin‑dependent type 2 diabetes. The business model centres on device sales and recurring pod consumables, with supplementary software and services that support automated insulin delivery. With a market capitalisation of roughly $23.2 billion, growth prospects hinge on rising adoption of insulin‑delivery technology, tighter integration with continuous glucose monitoring and expansion into international markets. Key investor considerations include manufacturing scale‑up, reimbursement and regulatory pathways, competition from established pump makers and integrated diabetes platforms, and execution risk around new product roll‑outs. Financial performance can be variable and past performance is not a guarantee of future returns. This is general educational information only and not personal advice; investors should assess suitability for their own circumstances and may wish to consult a regulated financial adviser.
Why It’s Moving
PODD is still moving on a sharp earnings reset, with growth strength now battling softer guidance and legal noise.
- Insulet’s early-August earnings showed solid top-line growth, but management’s cut to U.S. Omnipod guidance raised questions about retention and usage trends in the company’s fastest-moving segment.
- The market also has to absorb a wave of class-action lawsuit headlines tied to alleged disclosure issues, adding a legal overhang that can keep sentiment fragile even after a strong quarterly beat.
- Recent trading suggests investors are still weighing the tension between strong underlying demand for Omnipod and the softer U.S. outlook, which has made the stock more reactive to every new headline.
PODD is still moving on a sharp earnings reset, with growth strength now battling softer guidance and legal noise.
- Insulet’s early-August earnings showed solid top-line growth, but management’s cut to U.S. Omnipod guidance raised questions about retention and usage trends in the company’s fastest-moving segment.
- The market also has to absorb a wave of class-action lawsuit headlines tied to alleged disclosure issues, adding a legal overhang that can keep sentiment fragile even after a strong quarterly beat.
- Recent trading suggests investors are still weighing the tension between strong underlying demand for Omnipod and the softer U.S. outlook, which has made the stock more reactive to every new headline.
Sixth Month Growth Performance
When is the next earnings date for INSULET CORPORATION (PODD)?
The next earnings date for PODD is expected to be October 29, 2026, based on current market consensus calendars. It should cover the third quarter of 2026. This timing is consistent with the company’s usual late-October reporting pattern after its August 5, 2026 Q2 release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Insulet's stock with a target price of $259.65, indicating significant potential growth.
Financial Health
Insulet Corporation is performing well, with strong profits and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth from Adoption
Increasing uptake of insulin‑delivery technology could drive revenue through devices and recurring pods, though adoption rates and reimbursement vary by market.
International Expansion
Rolling out into new regions offers scale potential, balanced against regulatory approvals, local reimbursement and distribution challenges.
Innovation & Partnerships
Integration with continuous glucose monitors and progress toward automated insulin delivery can be strategic catalysts, yet execution and competition are material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
